Malignant cells show increased glucose uptake in vitro and in vivo. High expression of the glucose transporter-1 gene (GLUT1) has been found in many human tumor tissues. The aim of this study was to investigate the correlation between GLUT1 expression in breast carcinomas of Taiwanese patients and clinical prognostic parameters. Twenty-eight (71.8%) of the 39 breast carcinomas analyzed showed positive GLUT1 expression with different intensities: 1ϩ, 19 cases (48.7%); 2ϩ, 6 cases (15.4%), 3ϩ, 3 cases (7.7%). No significant correlation was seen between GLUT1 expression and clinical prognostic parameters such as tumor size (p ϭ0.085), age (p ϭ0.4528), axillary lymph node metastasis (p ϭ0.9562), nuclear grade (p ϭ0.6895), estrogen receptor-positive (p ϭ1.0000), and progesterone receptor-positive (p ϭ0.9689).
Malignant cells show increased glucose uptake both in vitro and in vivo [1, 2] . This uptake is mediated by glucose transporters (GLUT), while expression and activity are regulated by oncogenes and growth factors [3] [4] [5] [6] . GLUT1, the human erythrocyte glucose transporter, is a member of the facilitative glucose transporter family, which is composed of six members [7] . The physiologic expression and immunohistochemical detection of GLUT1 are demonstrated in red blood cell membranes, brain capillary endothelium (the bloodbrain barrier) [8] , the perineurium of the peripheral nerve (all interface with cells or tissues with glucosederived metabolism) [9] , placenta [10] , and basal cells of benign squamous epithelium [11] . A number of immunohistochemical studies have demonstrated aberrant expression of GLUT1 in epithelial neoplasms, as well as a correlation between GLUT1 expression and neoplastic progression [11] [12] [13] [14] [15] [16] [17] . GLUT1 have also been detectable in over 50% of head and neck cancers [18] , renal cell carcinoma [19] , malignant endometrial epithelia [20] , non-small cell lung carcinoma [21] , esophageal Barrett-associated adenocarcinoma [22] , papillary thyroid carcinoma [14] , cholangiocarcinomas [17] , and breast carcinomas [23, 24] .
The incidence of breast cancer has been increasing in Taiwan. In patients with breast cancer, mastectomy combined with chemotherapy and/or radiotherapy leads to the achievement of high response rates and prolongs survival. Modern treatment approaches for breast cancer require individual determination of the therapeutic strategy, in accordance with tumor stage and prognosis. Several factors are reportedly predictive of tumor response to chemotherapy and subsequent patient survival. These factors include the proliferation rate, estrogen and progesterone levels, gene p53, and the proto-oncogene c-erb B2 [25] .
According to previous studies, aberrant expression of GLUT1 in epithelial neoplasms as well as a correlation between GLUT1 expression and neoplastic progression have been found. The aim of our study was to investigate the relationship between the GLUT1 gene and the progression of breast cancer.
MATERIALS AND METHODS
We examined the expression and distribution of the GLUT1 gene and its relationship to clinicopathologic parameters in patients with breast cancer. GLUT1-positive and GLUT1-negative carcinomas were analyzed for their clinicopathologic characteristics including tumor size, age, lymph node metastasis, estrogen receptor (ER), progesterone receptor (PR), and nuclear grade.
Tissue
Thirty-nine formalin-fixed, paraffin-embedded breast cancer tissues and 39 breast carcinoma tissue sections containing normal tissue were examined by GLUT1 immunohistochemical staining ( Figure) . All patients were between the ages of 29 and 82 years and underwent partial or total mastectomy at the China Medical University Hospital in Taichung, Taiwan between December 1999 and December 2001.
Immunohistochemistry
Three to four sections (m) of tissues were cut and mounted onto poly-L-lysine-coated slides (DAKO, Copenhagen, Denmark). The tissue sections were dewaxed in two changes of xylene and placed in absolute ethanol for 1 minute. The sections were immersed in flowing water for 2 minutes, and then microwaved in the retrieval solution (DAKO) for 12 minutes. After microwaving, the sections were immersed in distilled water with 3% hydrogen peroxide for 10 minutes to block endogenous peroxidase activity in the tissue. After three 2-minute washes in phosphate-buffered saline (PBS), the sections were covered with 100 L of serum-blocking solution (ZYMED NBA TM KIT; Zymed Laboratories Inc, South San Francisco, CA, USA) for 10 minutes to reduce background staining. Any excess serum blocking solution was drained, and the sections were incubated with a 1:400 dilution primary antibody GLUT1 (DAKO) for 60 minutes at 25ЊC. Following three 2-minute washes in PBS, the sections were incubated with 100 L of secondary antibody (ZYMED NBA TM KIT) for 10 minutes. After three 2-minute washes in PBS, the sections were incubated with 100 μL of tertiary antibody-enzyme conjugate (ZYMED NBA TM KIT) for 10 minutes. After three 2-minute washes in PBS, the sections were immersed in a DAB solution (ZYMED kit) for 5 minutes. Finally, after three 2-minute washes in distilled water, the sections were counterstained with Mayer's hematoxylin (Sigma Chemical Co, St Louis, MO, USA), dehydrated through increasing concentrations of ethanol, and then mounted. Placenta tissue was used as the antibody concentration test and positive control for each experiment as illustrated in part A of the Figure. Membranous staining in tumor cells was indicative of GLUT1 expression.
Positive/negative
Tumors were determined positive if any tumor cells stained brown, or negative if tumor cells did not stain brown. All determinations were made by a pathologist.
Intensity of staining
The intensity of tumor staining was graded on a scale of 0-3, wherein 0 ϭ no positive staining of tumor cells; 1 ϭweak positive staining; 2 ϭmoderately strong positive staining; and 3 ϭstrong positive staining of tumor cells.
Statistical analysis
The expression of GLUT1 was compared with clinicopathologic features such as tumor size, lymph node metastasis, ER, PR, and nuclear grade. All statistical tests were performed by either the Fisher's exact or 2 tests; p values Ͻ0.05 were considered statistically significant. tissues were examined by GLUT1 immunohistochemical staining (Figure) . Twenty-eight (71.8%) of the 39 breast carcinomas showed positive GLUT1 expression with varying degrees of intensity: 1ϩ, 19 cases (48.7%); 2ϩ, 6 cases (15.4%), 3ϩ, 3 cases (7.7%) ( Table 1) .
The correlations between GLUT1 expression and several clinicopathologic prognostic parameters are shown in Table 2 . There were no significant differences in GLUT1 expression and tumor size (p ϭ 0.085), age (p ϭ0.4528), axillary lymph node metastasis (p ϭ0.9562), nuclear grade (p ϭ0.6895), ER positivity (p ϭ 1.0000), and PR positivity (p ϭ0.9689). At the 2-year follow-up, breast carcinoma recurred in 6 (15.4%) cases and the overall survival rate was 89.7%. There was no correlation between GLUT1 expression and either recurrence (p ϭ1.0000) or survival rate (p ϭ 0.4528).
DISCUSSION
Increased rates of glycolysis in cancer cells provide an adequate supply of energy, enabling malignant cells to survive and proliferate. In a study by Brown et al, the expression of GLUT1 in breast cancer tissues was highly heterogeneous in both the extent and intensity of staining [26] . In our study, the cell membrane and the cytoplasmic granules were GLUT1positive in all breast cancer cells. The percentage of GLUT1-positive tissues (71.8%) was higher than that reported for the same antibody by Kang et al (47%) [27] . These differences may have been related to differences in patient populations or tumor types. Some normal and hyperplastic mammary epithelial cells in tumor-free areas were GLUT1-positive; however, the intensity of staining in these cells was lower than in cancer cells. GLUT1-positive normal mammary cells exhibited a diffuse cytoplasmic staining, unlike the cancer cells, and their cell membranes were GLUT1 negative. Kang et al found that GLUT1 expression correlates with negative ER, negative PR, high nuclear grade, and poor disease-free survival [27] . Although the same antibody was used, there were no statistically significant findings in our study. A possible explanation may be that the patient population differed in each study. With the exception of three patients, the breast tumor cell types in our study were all invasive ductal carcinoma. The expression and activity of facilitative glucose transporters is regulated by various types of oncogenes and growth factors. Perhaps different environmental signals induce GLUT1 expression. Artificial menopause (surgical oophorectomy or radiation ovarian ablation) before the age of 35 years, increasing parity, young age (Ͻ30 years) at first pregnancy and breast-feeding are protective factors against developing breast cancer. Conversely, breast cancer is more common in women with an early menarche or a late menopause. In addition, women (Ͼ60 years) may be at increased risk of developing breast cancer. In our study, no statistically significant correlation was found between GLUT1 expression and age (p ϭ0.4528). However, this may have been due to the small sample size. In our study, 28 (71.8%) of the 39 breast carcinomas showed positive GLUT1 expression. However, no significant correlation was seen between GLUT1 expression and either clinical prognostic parameters, recurrence rate, or survival rate. 
